J.&J 主要工場での新型コロナワクチン製造中止へ

 

J.&J. Pauses Production of Its Covid Vaccine Despite Persistent Need

A crucial Johnson & Johnson plant has stopped making its Covid vaccine, though the company says it has millions of doses in inventory.

The American company, which has already fallen far behind on its deliveries to poorer countries, late last year quietly shut down the only plant making usable batches of the vaccine, according to people familiar with the decision.

The facility, in the Dutch city of Leiden, has instead been making an experimental but potentially more profitable vaccine to protect against an unrelated virus.

But over the next several months, the interruption has the potential to reduce the supply of Johnson & Johnson’s Covid vaccine by a few hundred million doses, according to one of the people familiar with the decision. Other facilities have been hired to produce the vaccine but either aren’t up and running yet or haven’t received regulatory approval to send what they’re making to be bottled.

Inside Johnson & Johnson’s executive suites, the decision to suspend production at Leiden prompted concerns that it would impair the company’s ability to deliver on its vaccine commitments to the developing world.

“This is not the time to be switching production lines of anything, when the lives of people across the developing world hang in the balance,” said Dr. Ayoade Alakija, a co-head of the African Union’s vaccine-delivery program.

Jake Sargent, a spokesman for Johnson & Johnson, said in an email that the company was “focused on ensuring our vaccine is available where people are in need” and that its global production network “is working day and night” to help fight the pandemic.

He said the company was continuing to deliver batches of the vaccine to facilities that bottled and packaged doses. He also said Johnson & Johnson had millions of finished doses in inventory.

https://www.nytimes.com/2022/02/08/business/johnson-johnson-covid-vaccine.html

 

Americans who received the one-dose Johnson & Johnson COVID-19 vaccine were 3.5 times as likely to develop rare blood clots compared to the general population, study finds

• Recipients of the J&J COVID-19 vaccine are 3.5 times as likely to develop a rare, deadly, blood clotting condition than the general population, a new study finds
• Researchers found that 8.5 J&J recipients developed the clots for every 100,000 person years, compared to only 2.5 out of the general population
• Researchers found that women between aged 30 and 64 were most at risk of developing the clotting 
• Authorization of the vaccine was paused for ten days during April due to concerns of the blood clotting developing in women 
• Cerebral venous sinus thrombosis, or CVST, is a dangerous condition that can cause a person to suffer stroke, or even die

By Mansur Shaheen U.S. Deputy Health Editor For Dailymail.Com

Published: 11:00 EST, 1 November 2021 | Updated: 14:58 EST, 1 November 2021

 https://www.dailymail.co.uk/health/article-10152723/Americans-received-one-dose-J-J-Covid-vaccine-3-5-times-likely-develop-blood-clots.html

2022年2月10日木曜日

たぶんDeath汁接種者はほぼ全員、m1Ψとスパイクタンパク質により血栓性微小血管障害症が発症し破砕赤血球が出現している

https://tokumei10.blogspot.com/2022/02/deathm1.html

 Yoshiki・・・（爆ｗｗｗｗｗｗｗ